

Day	Time	Topic	Speaker
<b>Monday 13<sup>th</sup> September 2010</b>	12:00	Lunch	
	14:30	Closed Meeting of Steering Committee and Organizing Committee	
		Pre-AGM-issues – Organizing Committee	<b>Dr. G. V. J. A. Harshavardhan</b> Bharat Biotech, Hyderabad
		Issues for DCVMN Executive Committee for 2011	
		1. Adoption of amended Bye-Laws	<b>Ms. Mahima Datla</b> General Secretary, DCVMN
		2. Expansion of Membership	
		3. New Secretariat	
		* Selection & nomination * New place for Secretariat * New role for Secretariat * Budget for Secretariat	
		4. Discussion on improvement of DCVMN governance	
		5. Participation of DCVMN members in the international forums	
		6. Other issues	
	18:30	Cocktail & net-working dinner. SC to suggest names. DCVMN members already arrived. Sponsors to be included	
	<b>Note:</b> This page is for distribution to DCVMN Member Companies and <b>Dr. Susan McKinney</b> only – No Resource Members		



Day	Time	Topic	Speaker
<b>Tuesday 14<sup>th</sup> September 2010</b>	07:30	DCVMN members ONLY register for AGM	
	08:30	Introductory Remarks Welcome by the Host and Meeting Organizer	<b>Dr. Akira Homma</b> , President, DCVMN <b>Dr. Krishna M. Ella</b>
	08:40	Overview of SAGE and Other Issues	<b>Dr. Akira Homma</b>
	08:55	GAVI- Update and overview on strategic issues for DCVMN Members	<b>Dr. Suresh S. Jadhav</b> , DCVMN / GAVI
	09:15	Discussion	
	09:20	Report – Budget issues; New Members; Release of DCVMN Directory other issues	<b>Ms. Mahima Datla</b> , DCVMN General Secretary
	09:40	Coordination of the Session	<b>Dr. Susan McKinney</b> , Coordinator
	<b>Hard issues and brainstorming: the role of DCVMN in the global market and supply of vaccines.</b>		Rapporteurs:
		Small Groups' work. One or two SC members to lead a Group. Each Group will tackle one – two issues	
		Some possible issues to be addressed	
		* What are the major issues for WHO Pre-Qualification?	
		* What are the major challenges to come into global vaccine market ?	
		* What are the issues and obstacles that preclude taking advantage of existing opportunities in the global vaccine market ?	
		* Are the multilateral institutions, namely WHO, UNICEF collaborating with DCVMN Members?	
		* How should the participation of DCVMN Members at GAVI be addressed?	
		* How AMC could contribute to expand DCVMN operation into GAVI ?	
		* How to improve cooperation and networking among DCVMN Members?	
		* Is there a possibility to produce a new product required by the global market in cooperation among DCVMN laboratories?	
		* What are the major issues that preclude the incorporation of the new technologies of vaccine production?	
		* What are the critical success factors for partnerships between emerging countries' manufacturers to address public health needs in the vaccine industry?	
		* How can the international and multilateral organizations contribute better to address the need of expansion of DCVMN production capacity?	
		* Other issues considered important to be addressed and discussed.	

Day	Time	Topic	Speaker
<b>Tuesday 14<sup>th</sup> September 2010</b>		Suggest Small Group works around 3 – 5 topics (depending on the number of members present). Each group will be led by one or two SC members and have a Rapporteur to present summary of Discussion.	
		All DCVMN members should participate in this session. This is just an idea. Your comments are welcome....	
		<b>PRESS CONFERENCE</b>	
	<b>12:30</b>	<b>Lunch</b>	
	13:30	Rapporteurs' reports and discussion	
	<b>15.00</b>	<b>Coffee Break</b>	
	15:30	Dr. Susan Mckinney summarizes	
	16.00	Presentations by Sponsors	
	17:30	AGM Adjourns (Steering Committee will gather to meet with Dr. Susan Mckinney to briefly discuss outline of 2 summary document)	
	<b>19:00</b>	<b>Dinner</b>	

Day	Time	Topic	Speaker
<b>Wednesday 15<sup>th</sup> September 2010</b>	08:20	<b>INAUGURATION and INTRODUCTION</b>	<b>Dr. Akira Homma</b> , President
		<b>Prof. N. K. Ganguly</b> Distinguished Biotech Fellow & Advisor Translational Health Science Technology Institute, New Delhi	
		<b>Dr. Marie-Paul Kieny</b> , Director, Initiative for Vaccine Research, WHO	
		<b>Dr. Akira Homma</b> , Chairman of Policy & Strategy Council, BioManguinhos / Fiocruz, Rio de Janeiro, President, DCVMN	
		<b>Ms. Mahima Datla</b> , Senior Vice-President, Biological E, Hyderabad, General Secretary, DCVMN	
		<b>Dr. Suresh S.Jadhav</b> , Executive Director, Serum Institute of India, Pune, DCVMN Representative to GAVI	
		<b>Dr. Krishna M. Ella</b> , Chairman & Managing Director, Bharat Biotech, Chairman Organizing Committee (Lighting of the Lamp. Presentation of garlands/bouquets. Brief introduction of the dignitaries)	
	08:30	Welcome Address	<b>Dr. Krishna M. Ella</b> CMD, Bharat Biotech
	08:38	Opening Address	<b>Dr. Akira Homma</b> President
	08:45	Key Note Address	<b>Prof. N. K. Ganguly</b>
	09:15	Coffee Break	
		<b>Session I Global Immunization</b>	Coordinator: <b>Ms. Mahima Datla</b> Rapporteur: <b>Mr. Sai D. Prasad</b>
	09:30	Global Overview on Immunization	<b>Dr. Thomas Cherian</b> , Coordinator, WHO, Geneva
	10:00	Discussion	
	10:10	Improving access to key vaccines for low income markets: A donor perspective	<b>Mr. Gerard Cunningham</b> , Senior Program Officer, Bill & Melinda Gates Foundation, Seattle
	10:40	Discussion	
	10:50	Vaccine forecast: Present and Future, role of DCVMN manufacturers in vaccine supply	<b>Mr. Robert Matthews</b> , Contracts Officer, UNICEF, Copenhagen
	11:20	Discussion	
	11:30	Sabin-IPV technology and the role of DCVMN's in IPV supply	<b>Prof. Dr. Claire Boog</b> Scientific Director, Netherlands Vaccine Institute, Bilthoven.
	12:00	Discussion	
	12:10	Lunch	

Day	Time	Topic	Speaker
<b>Wednesday 15<sup>th</sup> September 2010</b>		<b>Session II Global Vaccine Market and DCVMN Role</b>	Coordinator: <b>Mr. Selwyn Kahanovitz</b> Rapporteur : <b>Dr. Harshavardhan</b>
	13:10	GAVI Strategic Plan (2010-2015) and the role of DCVMN laboratories	<b>Dr. Jonathan, Pearman</b> GAVI, Geneva
	13:40	Discussion	
	13:50	Emerging Vaccine Markets and Emerging Manufacturers: What are the trends, potentialities and issues	<b>Mr. Miloud Kadder</b> , Group Leader EPI/IVB/FCH, WHO, Geneva
	14:20	Discussion	
	14:30	Vaccine market trends: Challenges and Opportunities	<b>Dr. Erica Monfardini</b> Life Sciences & Pharma Practice PriceWaterhouseCooper, Luxembourg
	14:50	Discussion	
		<b>Session III WHO Pre-Qualification, WHO Standards &amp; Vaccine Stability</b>	Coordinator: <b>Mr. R. K. Suri</b> Rapporteur : <b>Dr. V. K. Srinivas</b>
	15:00	Proposed revision of WHO PQ requirements	<b>Dr. Nora Dellepiane</b> Scientist, Group Leader/QSS/IVB, WHO, Geneva
	15:30	Discussion	
	15:40	Update on the development and implementation of WHO International Standards for Vaccines and some Biotherapeutics	<b>Dr. Ivana Knezevic</b> Scientist, QSS/WHO, Geneva
	16:10	Discussion	
	16:20	Making optimal use of the real heat stability of vaccines in low and middle income countries.	<b>Mr. Michel Zaffran</b> , Director, Project Optimize /IVB,WHO, Geneva
	16:50	Discussion	
	17:00	NRA status in the world and impact on viability of vaccine production and global vaccine supply	<b>Dr. Belgharbi Lahouari</b> IVB/WHO, Geneva
	17:30	Discussion	
	17:40	Update information on VPGG and the role of DCVMN laboratories.	<b>Mr. Selwyn Kahanovitz</b> Group CEO, The Biovac Institute, Wadeville
	18:00	Discussion	
	18:10	Policy changes ideas to address the need of developing countries in regards to vaccine availability, adaptability and price	<b>Dr. Paul Wilson</b> Assistant Professor, Columbia University, New York
	18:40	Discussion & Adjourn	
	18:50	Presentation of the Best Scientist Award to DCVMN-India Scientist Release of DCVMN Directory	<b>Dr. Akira Homma</b> , President
	19:30	<b>Light Music &amp; Dinner hosted by Bharat Biotech</b>	<b>Boulder Hills Golf and Country Club Hyderabad</b>

Day	Time	Topic	Speaker
<b>Thursday 16<sup>th</sup> September 2010</b>		<b>Session IV Blink in to the future Innovation &amp; technological development in the field of vaccines and biotechnology</b>	Coordinator: <b>Dr. Suresh S. Jadhav</b> Rapporteur : <b>Dr. G. Ravi</b>
	09:00	Developing vaccines for Global Health.	<b>Dr. Altaf Lal</b> , CEO, Hilleman Laboratories, New Delhi
	09:30	Transmission Blocking Vaccines for Malaria produced in plants.	<b>Dr. Vidadi Yusibov</b> , Fraunhofer Centre of Molecular Biology, Newark
	09:50	Discussion	
	10:00	TBVI Tuberculosis Vaccine Initiative	<b>Dr. Micha Roumiantzeff</b> TBVI / PDT Member, Lelystad
	10:20	Discussion	
	10:30	Innovative Approaches to Accelerate Vaccine Development for Low- Resources Countries.	<b>Dr. John W. Boslego</b> Director, Vaccines, PATH, Seattle
	10:50	Discussion	
	<b>11:00</b>	<b>Coffee Break</b>	
	11:15	PATH's Vaccine Technology Projects.	<b>Dr. Darin Zehrung</b> Portfolio Leader, PATH, Seattle
	11:35	Discussion	
	11:45	Results of H1N1 Preclinical Studies.	<b>Dr. Luciana C.C.Leite</b> , Director, Center of Biotechnology, Instituto Fundacao Butantan, Sao Paulo
	11:55	Discussion	
	12:05	Hepatitis E Vaccine.	<b>Dr. Wu Ting</b> , Manager Medical Affairs, Xiamen Inovax Biotech, Xiamen
	12:25	Discussion	
	12:35	Chikungunya Vaccine.	<b>Dr. K. Sumathy</b> , Associate Director, Bharat Biotech, Hyderabad
	12:55	Discussion	
	<b>13:00</b>	<b>Lunch</b>	
		<b>Session V Emerging Vaccines</b>	Coordinator: <b>Dr. Luciana CC Leite</b> , Director, Center of Biotechnology. Rapporteur : <b>Dr. G. Kamaraj</b>
	14:00	Rotavirus vaccine (Ruth Bishop Strain)	<b>Dr. Mahendra Suhardono</b> , Production Director, PT. Bio Farma, Bandung
	14:10	Discussion	
	14:20	Bio-Manguinhos/Finlay Institute Technical Cooperation for Menigitis A/C vaccine production	<b>Dr. Maria da Luz Fernandes Leal</b> Deputy Director of Quality, Rio de Janeiro
	14:40	Discussion	
		<b>Session VI: DCVMN Reflections on 11th Conference (DCVMN MEMBERS only)</b>	Coordinator: <b>Dr. Zeng Bing</b> Vice President, China National Pharmaceutical Corporate Group, Beijing Rapporteur: <b>Dr. A. D. Sarma</b>
	14:50	Current status and future directions of DCVMN & Remaining issues	Discussion by DCVMN Members
	15:20	Closing Remarks	<b>Dr. Akira Homma</b> , President
	15:30	Leave for site visit to <b>Bharat Biotech</b> and <b>Biological E.</b>	
	<b>20:30</b>	<b>Dinner</b>	